NCT01689909
Reducing Suicidal Ideation Through Insomnia Treatment
See it on ClinicalTrials.gov ↗103 people
62.1%
37.9%
64 womenmiddle line = equal numbers39 men
- Phase
- PHASE4
- Paid for by
- Augusta University
- Finished
- 2018-01-01
- Health conditions
- Insomnia, Depression, Suicidal Ideation
- Who could join
- Anyone
- Ages
- 18 Years – 65 Years
- Average age
- mean 40.5 years
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 66% · Black / African American 27.2% · Asian 6.8% · American Indian / Alaska Native 0% · Native Hawaiian / Pacific Islander 0% · More than one race 0% · Not reported 0%
Women left out
- No pregnant women
Women who were pregnant could not join.
“Persons who might be harmed by exposure to hypnotics, including pregnant women and patients with respiratory conditions”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“Persons free of all psychotropic medications for one week before baseline assessment, except that prior FLX treatment will require 4 weeks of abstinence, and MAOIs will require 2 weeks of abstinence.”
- Weight limit (BMI)
Women with a higher (or lower) body weight were turned away.
“Persons with BMI \> 50”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Persons with severe suicidal ideation (C-SSRS Suicidal Ideation Score \>3)”
Study titles and rules are shown in their original English.